Interestingly, experimental data showed that pharmacological activation of PERK rescued neuronal cells in in vitro and in vivo models of tauopathies (Bruch et al. 2017), suggesting that PERK activation might be a rational approach for a neuroprotective therapy of PSP and other tauopathies. The gene discussed is EIF2AK3; the disease is tauopathy.